AG真人官方

NEW HAVEN, Conn., July 29, 2025 /PRNewswire/ --聽听(狈补蝉诲补辩: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio鈩� (oral nalbuphine ER) 聽for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will be participating in the following conferences in August.

Oppenheimer's 2025 Biotech in the Berkshires
August 4 鈥� 6, 2025, Berkshires, Massachusetts
Trevi Representative:聽Jennifer Good, President and CEO

Stifel's 2025 Biotech Summer Summit
August 11 鈥� 13, 2025, Newport, Rhode Island
Fireside Chat:聽August 11, 1:00 p.m. ET
Trevi Representatives: Jennifer Good, President and CEO, and Farrell Simon, Pharm.D., CCO

About Trevi Therapeutics, Inc.听听听听
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio鈩� (oral nalbuphine extended-release) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). Haduvio is the first and only investigational therapy to show a statistically-significant reduction in cough frequency in clinical trials of patients with IPF chronic cough and in patients with RCC. Haduvio acts on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA), targeting opioid receptors that play a key role in controlling chronic cough. Nalbuphine is not currently scheduled by the U.S. Drug Enforcement Agency.听

Chronic cough is a highly prevalent condition, impacting up to 85% of patients with IPF. There are ~150,000 patients in the U.S. with IPF. The impact of chronic cough is significant with patients coughing up to 1,500 times per day. This consistent cough and any associated damage may lead to worsening disease, a higher risk of progression, death, or need for lung transplant. Chronic cough also often leads to a decline in patients' social, physical, and psychological quality of life. There are no approved therapies for the treatment of chronic cough in patients with IPF and current off-label treatment options provide minimal benefit to patients.

Refractory chronic cough has no approved therapies in the U.S. and is defined as a persistent cough lasting >8鈥厀eeks despite treatment for an underlying condition (i.e., asthma, gastroesophageal reflux disease, non-asthmatic eosinophilic bronchitis, and upper airway cough syndrome or post-nasal drip) and includes unexplained chronic cough. RCC affects ~2-3 million patients in the U.S. and is caused by cough reflex hypersensitivity in both the central and peripheral nerves. It is a highly debilitating disease and accompanied by a wide range of complications, ranging from urinary incontinence in females to sleep disruption and social embarrassment that causes significant social and economic burdens for patients and those around them.听

Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority.听

For more information, visit聽聽and follow Trevi on聽聽(formerly Twitter) and聽.听

Investor Contact鈥���
Jonathan Carlson鈥���
Trevi Therapeutics, Inc.鈥���
(203) 654 3286鈥���
[email protected]

Media Contact鈥���
Rosalia Scampoli鈥���
914-815-1465鈥���
[email protected]

View original content to download multimedia:

SOURCE Trevi Therapeutics, Inc.